# Introduction orld Health Organisation (WHO) on January 30 2019, declared the outbreak of corona virus disease caused by the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) as international public health crisis. The first case of SARS-CoV-2 was reported in China in December 2019 which has expeditiously spread to the other countries and continents affecting highest number of population 1 . In a 3 months span of its first appearance in Wuhan, China, it was declared as Pandemic by WHO. In India about 3-10% patients are requiring intubation and 10-20% are requiring ICU admission 2,3 . The mortality rate was 49% 4 . The disease is characterised with dysregulated immune response with elevation in the levels of cytokines likeIL6, IL10, CXCL 10, lymphopenia and neutrophilia along with the systemic inflammation as seen by elevations in the levels of CRP, D-dimer, LDH, Ferritin. Lungs being the primary organ effected later leading to multi organ dysfunction 5 . To combat the disease several new molecular entities are being developed. On the basis of pathophysiology of the disease, it was thought that extra corporeal therapies specially designed to filter the cytokines can provide a hope in treating the critically ill COVID 19 patients and prevent organ failure and improve survival rate 6 . The same is demonstrated and supported by Ronco et al & Tay et al in their studies and clinical experience 7,8 . One such extracorporeal therapy designed to filter the cytokines was Cytosorb. Cytosorb was incorporated into the treatment guidelines in the early of the pandemic by several national medical societies. Use of cytosorb in COVID 19 patients with AKI (Acute Kidney Injury) stage 3 and are with Continuous Renal Replacement Therapy (CRRT) was first recommended by Italian Society of Nephrology 9 . USFDA also approved the usage of Cytosorb in critically ill COVID-19 patients on April 10, 2020 10 . In 2011, Cytosorb was originally approved by the European Union for treating the systemic hyperinflammation and refractory shock. Cytosorb is an extracorporeal cytokine adsorption cartridge with blood compatible porous polymer beads used as an adsorptive material in this blood purification technology 11,12 . Through this highly porous polymer beads, Cytosorb can continuously remove molecules upto 50kD and help in treating certain conditions like hypercytokinemia and in conditions like severe inflammatory response 13 . Each adsorber cartridge can be used for 24 hours and then need to be replaced with another. The flow rate to be maintained is between150-700 ml/min and can be used as standalone approach in hemoperfusion technique or can be connected into ECMO or CRRT circuit 12 . This therapy aids in removal of cytokines from the blood stream through concentration gradient and the binding of molecules to the adsorptive polymer is size dependent making it a broad-spectrum purification technique 14 . The current study is to demonstrate the effect of Cytosorb in severe COVID 19 patients in terms improvement according to 9-point ordinary scale developed by WHO 15 The outcome is measured in terms of reduction in the levels of inflammatory markers (C-Reactive Protein/CRP, D-dimer & IL6) before & after the therapy. The day of therapy is considered as D0 and the following post administration days as D+1, D+2, D+3, and so on. The levels of inflammatory markers and the scores according to the WHO ordinary scale on the D+1, D+3 and D+5 was observed and noted. The baseline value of each inflammatory marker is calculated by taking the average of the last 3 values before D0 which is considered as the mean value before the therapy. Similarly, taking the levels on the time points of our study (D+1, D+3 & D+5) another average value is calculated which is taken as the mean value post therapy. These 2 average values are compared to establish the role of Cytosorb in reducing the levels of inflammatory markers. The trend of reduction in the values is statistically tested using annova single factor assay. In case of WHO ordinary scale score, the score on D0 and on 3 time points were taken directly (without calculating the average score value) to establish the cytosorb role in reducing the score value. The outcome of the patient on D+7viz, out off NIV or MV or Death (7-day survival rate) & duration of ICU stay is observed. # f) Procedure After applying the inclusive and exclusive criteria individual patients given with respective number, P1, P2 & P3, in the sequence of their inclusion in the study. All the patients received SoC which included Oxygen support to maintain SpO 2 ? 93%, Glucocorticoid; Dexamethasone (0.2-0.4 mg/kg/day), Remdesivir (200mg stat dose followed by 100mg once daily for 4 days to a cumulative dose of 600mg given in 5 days), i.v. Antibiotics at physician discretion (when a bacterial infection is suspected), prophylactic dose of low molecular weight heparin/ Unfractionated heparin with dose adjusted according to the body weight and renal function of the individual patient, along with symptomatic treatment that includes antitussives, antihistamines, antipyretics, etc. In addition to the SoC, patients who are on NIV/ MV are randomly selected for treating with cytosorb after explaining the risks and benefits associated with the therapy. Cytosorb therapy is given as stand-alone treatment with blood pumps in hemoperfusion mode. The flow rate of the cytosorb was set to 150-200ml/min with unfractionated Heparin of 5000 IU as prophylaxis & to a duration of 8-12 hours depending on the clinical condition of the patient viz, elevated levels of markers, hemodynamics during the cytosorb, side effects to the therapy. The baseline values (Mean before the therapy) of the inflammatory markers along with the score according to the WHO ordinary scale are compared with that of on D+1, D+3 and D+5 to observe for any reduction in the values. # h) Statistical Analysis All the numerical data in the study, levels of inflammatory markers and score according to the WHO scale, are tested for statistically significant different across the time period using ANNOVA one-way methos in Microsoft Excel software. The p-value obtained by the test is used to confirm the assumed hypothesis, "levels of inflammatory markers/ score value according to the WHO ordinary scale are reduced upon cytosorb therapy". The p-value < 0.05 indicates the significant reduction in the values across the time period accepting the assumed hypothesis and vice-versa. Non numerical data, population out off NIV/ MV/ ICU 7 days after the procedure, are calculated as % population with the respective outcome. III. # Results Our study included 3 male patients, Patient 1 or P1, Patient 2 or P2 & Patient 3 or P3, of age 61, 36 & 49 respectively with mean age 48.6 years. All the patients presented to the ICU in the study period received Cytosorb therapy after 5-7 days of admission in the ICU. As detailed in the methodology and procedure sections, the baseline value of the levels of inflammatory markers are calculated and analyzed accordingly. The mean baseline value of CRP before therapy, was 63.3, 56.5 & 81 respectively for P1, P2 & P3. The mean average value of CRP after the therapy of P1, P2 & P3 was 50.5, 44.9 & 67.3 respectively. Figure 2 represents the mean levels of CRP before and after the therapy in all the 3 patients. The annova single factor assay done that resulted a p value of 0.60 reporting no statistically significant difference in the levels of CRP across the time period. Figure 3 shows the baseline levels of CRP of all the patients along with the levels on D+1, D+3 and D+5. The mean values of IL 6 levels before and after the therapy were almost similar with 124, 143& 167 and 126.33, 143& 141.3 before and after the therapy in P1, P2 & P3 respectively. Figure 6 represents the mean levels of IL6 before and after the therapy in all the 3 patients. Annova single factor assay done to test the statistically significant difference between the values reported 0.70 indicating no significant difference between the values across the time points. The 7-day outcome showed a complete mortality with 100% population (3 out of 3 patients) due to acute respiratory distress syndrome& AKI& cardiac arrest. The table 2 provides the summary of our study at a glance. # Discussion Despite the data relating to the use of Cytosorb usage in COVID is very limited, its application as a adjuvant therapy is been carried out at several educational institutions, being a new therapeutic approach in treating COVID 19 12 . A case series of COVID 19 patients along with AKI treated with CRRT+ cytosorb published by Alharthy et al. reported reduction in the inflammatory biomarkers and 70 % population with favorable results surviving the condition and 30% died despite the therapeutic approach 16 . The first randomized, prospective pilot study conducted to study the effect of cytosorb in COVID 19 patients reported significant improvement in terms of Procalcitonin levels and vasopressor requirements. However, this study did not look for any improvement in terms of other inflammatory markers, ICU admission, Mechanical ventilation support, limitations of the study according to us 17 . Another case series published by Mehtha et al., reported the use of Cytosorb after 72 hrs of ICU admission for 24 hrs reported a significant decrease in the levels of CRP and 100% survival rate 18 al, reported a case study of a 51 years old male COVID 19 patients who survived cytokine storm upon treating with Cytosorb and definite treatment 20 . Another case study conducted by Berlot et al, reported use of Cytosorb along with Tocilizumab reported a positive result in terms of extubation after 10 days of the therapy and radiological imaging suggestive of improvement in the lung fields 21 . Rieder et al. studied the use of Cytosorb incorporated in tht ECMO circuit in comparison with the ECMO alone in treating severly ill COVID 19 patients. The study resulted in the higher reduction in the levels of IL6 in Cytosorb + ECMO group than in ECMO alone treated group 22 . However use of Cytosorb on the first day of ECMO initiation is not suggested and can be incorporated into the ECMO circuit after 24 hours of initiation according to the studies conducted by Alexander Supady MD 23 . A comparative study conducted by Rampino T et al. reported the reduction of IL6, IL10, TNF ? and CRP in Cytosorb treated group in comparison to the control group. In test group, only 1 patient dies and 2 were intubated while that all of the patients in control group were intubated and died by the end of the study 24 . VI. # Conclusion A case cohort study conducted to establish the benefits of Cytosorb therapy in addition to the SoC in treating the severe COVID-19 illness in terms of reduction of inflammatory markers levels (CRP, D-DIMER, IL6), WHO score value along with the 7-day outcome of mortality or out off NIV/MV. The results of our study didn't show any additional benefits of adding the CYTOSORB therapy to the existing SoC in improving the clinical outcome with no statistically significance in reducing the levels of inflammatory markers and even WHO score value. However, the 7-day outcome of our study reported 100% mortality, to confirm the complete ineffectiveness of the therapy in severe COVID 19 patients a study on large group population is encouraged. ![on 1 day after administration (D +1) & 3, 5 days after administration (D +3, +5) along with reduction in the levels of inflammatory markers (CRP, D-DIMER & IL6) & 7 days outcome viz, out off NIV/ MV or Death & duration of ICU stay.](image-2.png "") ![d) Inclusive Criteria ? Patients who can afford the therapy. ? Patients with altered renal functioning. ? Patients with HRCT severity category& are on NIV/ MV. e) Exclusive Criteria ? Patients who cannot afford the therapy. ? Patients with low platelet count (<20,000/cumm). ? Pregnant women. ? Patients with known allergies for extra corporeal therapies. ? Hemodynamically unstable patients. ? Patients who are not requiring NIV/ MV.](image-3.png "") ![g) Measure of Outcome ? Score according to the WHO ordinary scale across the time period. ? Statistically significant reduction of inflammatory markers viz, C-Reactive Protein (CRP), D-DIMER& IL6, across the time period as tested using annova single factor assay along with reduction in mean before and mean after the therapy. ? Outcome of the patient 7 days after the procedure, viz, out off NIV/ IV/ ICU or death Note: The herein discussed CRP is measured in terms of mg/lit; D-dimer in µg/ml; IL 6 in pg/ml.](image-4.png "") ![Ventilation status of the patients on D0 are as ? P1 WAS ON MV ? P2 WAS ON NIV ? P3 WAS ON NIV Ventilation status of P1 & P2 was same till the end of the study while P3 progressed to MV on D+1. Annova single factor assay conduced to check the statistically significant reduction in the WHO score across the time period gave p value of 0.85 reporting no statistically significant difference. The figure 1 represents the fluctuation in WHO score value among the time line of the study.](image-5.png "") 1![Figure 1: Fluctuation in the WHO score value across the time period. Individual line represents the score values on the time points of the study of individual](image-6.png "Figure 1 :") 2![Figure 2: Mean of CRP before and after the therapy in all the 3 patients](image-7.png "Figure 2 :") 3![Figure 3: Levels of CRP across the time period. Individual line representing the levels of all the individual patient across the time points, viz, baseline, D+1, D+3 and D+5. The other inflammatory marker, D-dimer, mean before the therapy, was 331, 800 & 1211 of P1, P2 & P3 respectively and the mean value after the therapy was 243, 1040 & 932 respectively for P1, P2 & P3.The annova single factor assay conducted to test the hypothesis reported a p value of 0.95 stating there exists no statistically significant difference among the values of D-dimer across the study period. Figure 4 represents the trends of D-dimer levels of individual patients across the time points. Figure 5 represents the mean of D-dimer before and after the therapy in all the 3 patients.](image-8.png "Figure 3 :") 1 1Patient stateDescriptorScoreUninfectedNo clinical or virological evidence of0infectionAmbulatoryNo limitation of activities1Limitation of activities2Hospitalized mild diseaseHospitalized, no oxygen therapy3Oxygen by mask or nasal prongs4Hospitalized severe diseaseNon-invasive ventilation or high flow5oxygenIntubation or mechanical ventilation6Ventilation + additional organ7support-pressors, RRT, ECMODeadDeath8II.Methodsa) AimTo measure the efficacy of CYTOSORB therapyin reducing the levels of inflammatory markers in COVID19 patients.b) ObjectivesPrimary Objective: To establish the beneficial role ofCYTOSORB in addition to the Standard of Care inreducing the elevated levels of inflammatory markers insevere covid 19 patients along with getting the patientoff the NIV/ MV/ICU.Secondary Objective: To establish efficacy of Cytosorbtherapy in terms of improvement as per WHO scalescoring & duration of ICU stayc) MethodologyA case cohort study is conducted at MedisysHospitals, LB nagar, Hyderabad (city), Telangana(State), India (Country) to establish the beneficial role ofcytosorb in addition to the SoC in patients with severeCOVID 19 illness and those who are on NIV/ MV inreducing the levels of inflammatory markers and gettingthe patients off NIV/ MV.Study includes the patients admitted in ICUfrom 01-05-2021 to 31-05-2021 with RTPCR provenCOVID 19 illness and HRCT severity ?14 and are onNIV/ MV with age ? 35 years. 2PARAMETERPATIENT 1 OR P1PATIENT 2 OR P2PATIENT 3 OR P3STUDY GROUPAGE (YEARS)61364948.6SEXMALEMALLEMALED0655D+1656WHO SCALED+3656SCORED+5656D0 (mean before thetherapy)63.3356.581Mean after the therapy50.544.967.3CRPP value0.6D0 (mean before)3318001211Mean after the therapy2431040932D-DIMERP value0.95D0 (mean before)124143167Mean after the therapy126.33143141.3IL 6P value0.77 DAY OUTCOMEDEATHDEATHDEATHV. Volume XXII Issue V Version ID D D D ) F(Medical ResearchGlobal Journal of© 2022 Global Journals Year 2022 ## Acknowledgement I convey my sincere thanks to the managing director of the hospital Dr. Chandrashekar Reddy for allowing us to conduct the project. ## Conflict of Interest None. ## Funding The study did not receive any funding from any agencies or organisations. ## Informed Consent No informed consent is obtained since the study is an observational case cohort study. ## Ethical Statement Since no intervention is being done and informed consent form is obtained, our study do not require ethical statement. * Psychosocial impact of COVID-19 SDubey PBiswas RGhosh SChatterjee MJDubey SChatterjee DLahiri CJLavie Diabetes & Metabolic Syndrome 14 5 2020 Sep 1 Clinical Research & Reviews * Critical care for COVID-19 affected patients: position statement of the Indian Society of Critical Care Medicine. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine YMehta DChaudhry OCAbraham JChacko JDivatia BJagiasi AKar GCKhilnani BKrishna PKumar RKMani 2020 Apr 24 222 * Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series YMehta CMehta SNanda GKochar JVGeorge MKSingh Journal of medical case reports 15 1 2021 Dec * Coronavirus epidemic and extracorporeal therapies in intensive care: si vis pacem para bellum CRonco TReis DeRosa S Blood purification 49 3 2020 * SARS-CoV-2 and viral sepsis: observations and hypotheses. The Lancet HLi LLiu DZhang JXu HDai NTang XSu BCao 2020 May 9. 10235 395 * Extracorporeal blood purification and organ support in the critically ill patient during COVID-19 pandemic: expert review and recommendation CRonco SMBagshaw RBellomo WRClark FHusain-Syed JAKellum ZRicci TRimmelé TReis MOstermann Blood purification 50 1 2021 * Coronavirus epidemic: preparing for extracorporeal organ support in intensive care. The Lancet Respiratory Medicine CRonco PNavalesi JLVincent 2020 Mar 1 8 * The trinity of COVID-19: immunity, inflammation and intervention MZTay CMPoh LRénia PAMacary LFNg Nature Reviews Immunology 20 6 2020 Jun * Management of Patients on Dialysis and With Kidney Transplant During Covid-19 Coronavirus Infection. Brescia Renal Covid Task Force FAlberici EDelbarba CManenti LEconimo FValerio APola 2020 citado 2020 Ago 5 * The use of CytoSorb therapy in critically ill COVID-19 patients: review of the rationale and current clinical experiences JCRuiz-Rodríguez ZMolnar ENDeliargyris RFerrer Critical Care Research and Practice 2021 Jul 17; 2021 * First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection SFrimmel JSchipper JHenschel TTYu SRMitzner SKoball Liver Transplantation 20 12 2014 Dec * The use of CytoSorb therapy in critically ill COVID-19 patients: review of the rationale and current clinical experiences JCRuiz-Rodríguez ZMolnar ENDeliargyris RFerrer Critical Care Research and Practice 2021 Jul 17; 2021 * Rescue of cytokine storm due to HLH by hemoadsorption in a CTLA4-deficient patient CGreil FRoether LaRosée PGrimbacher BDuerschmied DWarnatz K Journal of clinical immunology 37 3 273 2017 Apr 1 * Effects of hemoadsorption on cytokine removal and shortterm survival in septic rats ZYPeng MJCarter JAKellum Critical care medicine 36 5 1573 2008 May * Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series. Artificial Organs AAlharthy FFaqihi ZAMemish ABalhamar NNasim AShahzad HTamim SAAlqahtani PGBrindley DKarakitsos 2021 May 45 * Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study FHawchar ILaszlo NÖveges DTrasy ZOndrik ZMolnar Journal of critical care 49 2019 Feb 1 * Use of CytoSorb therapy to treat critically ill coronavirus disease 2019 patients: a case series YMehta CMehta SNanda GKochar JVGeorge MKSingh Journal of medical case reports 15 1 2021 Dec * Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study SFriesecke SSStecher SGross SBFelix ANierhaus Journal of Artificial Organs 20 3 2017 Sep * Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report SRizvi MDanic MSilver VLabond Heart & Lung 50 1 2021 Jan 1 * The combined use of tocilizumab and hemoadsorption in a patient with SARS-COV-2-19-associated pneumonia: A Case Report GBerlot ATomasini ERPognuz ARandino FChiella LaFata CPiva MAmato P DiMaso VBianco FGerini U Nephron 144 9 2020 * Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation MRieder TWengenmayer DStaudacher DDuerschmied ASupady Critical Care 24 1 2020 Dec * Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. The Lancet Respiratory Medicine ASupady EWeber MRieder ALother TNiklaus TZahn FFrech SMüller MKuhl CBenk SMaier 2021 May 14 * Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia TRampino MGregorini LPerotti FFerrari EFPattonieri MAGrignano MValente AGarrone TIslam CLibetta VSepe Blood Purification 50 4-5 2021